# TOPIC 414 : SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY

> **NIH NIH N44** · SENTI BIOSCIENCES, INC. · 2021 · $1,999,993

## Abstract

The therapeutic administration of chimeric antigen receptor (CAR)-based cell therapies has considerably advanced the treatment of certain cancers. Unfortunately, the successes of CAR-based cell therapies have not yet translated to treatment of acute myeloid leukemia (AML), likely due to the lack of a suitable lineage antigen target. Due to their nonrestrictive expression, most AML antigens are also expressed on hematopoietic stem cells (HSCs), and thus on-target/off-tumor effects of the therapy may lead to the ablation of hematopoietic stem/progenitor cells, causing significant and life-threatening myelotoxicity and prolonged cytopenia. While there are currently dozens of clinical trials underway for various CAR-based therapies in AML patients, no treatment has yet demonstrated the ability to curb on-target/off-tumor killing of healthy HSCs.

## Key facts

- **NIH application ID:** 10498679
- **Project number:** 75N91021C00026-0-9999-1
- **Recipient organization:** SENTI BIOSCIENCES, INC.
- **Principal Investigator:** GARY LEE
- **Activity code:** N44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,999,993
- **Award type:** —
- **Project period:** 2021-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10498679

## Citation

> US National Institutes of Health, RePORTER application 10498679, TOPIC 414 : SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY (75N91021C00026-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10498679. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*